Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Treatment, Management Options for Difficult-to-Control Gout

Joan McTigue, PA-C  |  Issue: October 2014  |  October 1, 2014

When we saw him, he had no other medical problems, and his blood pressure and BMI were normal. His peripheral joints were all cool with full range of motion. He had no obvious tophi. His serum acid was 10.2 mg/dL. His renal function studies were normal. Risk factors included a family history of gout (i.e., his father) and heavy beer consumption, especially on weekends. He was a long distance truck driver.

We used this visit to educate him about gout, describing it as a chronic condition of excess urate burden, and emphasized our approach to management, stressing both short- and long-term goals. We hoped this would reduce future costly visits to the emergency department.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

He had already started taking colchicine 0.6 mg twice daily. We initiated allopurinol 100 mg daily with the goal of reducing his serum uric acid to less than 6.0 mg/dL. With slow allopurinol titration and continued flare prophylaxis, his uric acid slowly fell to 8.0 mg/dL.

Unfortunately, EH stopped coming to the clinic. Not surprisingly, his allopurinol prescription ran out, and his uric acid was never checked again. This is not an unusual situation for patients suffering from episodic attacks of gout. They wait until the pain returns before seeking medical attention.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Five years later, he enrolled with a primary care physician. By then he was experiencing monthly gouty flares affecting the great toes, the mid foot, the knees and the elbows. His job as a long-haul truck driver was becoming compromised.

Follow-up

EH was referred back to our rheumatology clinic by his primary care physician. He admitted that he had not taken allopurinol or colchicine for years. Instead, he had continued to seek flare-based episodic care in various parts of the country. This often consisted of intramuscular corticosteroids or methylprednisone dosepacks. At our visit, he had a significant knee effusion. Aspiration and synovial fluid analysis confirmed the presence of monosodium urate crystals. His uric acid that day was 10.2 mg/dL. Erosive changes in his right great toe were seen on X-ray. Showing him these images proved quite useful.

Once again, colchicine 0.6 mg BID and allopurinol 100 mg daily were restarted. A tapering dose of prednisone was added to provide immediate relief. He was counseled to curtail his beer drinking, and he freely admitted that this would be his toughest task.

Three weeks later he returned, feeling better, but with a resolving right elbow effusion. His uric acid was 11.0 mg/dL He was taking only 5 mg of prednisone daily. He had stopped the allopurinol because of nausea and the colchicine because he was afraid it would cause diarrhea. He had experienced significant diarrhea during one of his prior emergency department visits when he was prescribed an excessive dose of colchicine.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:crystal arthritisdrugGoutpatient careprednisonerheumatologistSteroidsTreatment

Related Articles

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Colchicine: An Ancient Drug with Modern Uses

    August 11, 2021

    Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

    Lost and found

    Understanding the Role of Uric Acid in Gout

    September 6, 2022

    From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences